Cedars-Sinai Medical Center

2024 Urology Care Foundation Research Scholar Awardees Announced

Retrieved on: 
금요일, 6월 14, 2024
Patient, Doctor of Philosophy, Urology, CO2, Pediatric urology, Kidney, Immunosuppression, AUA, Ureteroscopy, Female, UCF, Funding of science, Boston Children's Hospital, Society, University, Cedars-Sinai Medical Center, Research, Artificial intelligence, FACS, Kidney stone disease, Clinical professor, Hospital, American Urological Association, Prostate cancer, Diagnosis, Mayo Clinic, Ageing, Methylation, Listeria monocytogenes non-coding RNA, BBOX1, Bacteria, Urinary incontinence, Nursing

BALTIMORE, June 14, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 15 researchers as recipients of the 2024 Urology Care Foundation Research Scholar Awards.

Key Points: 
  • BALTIMORE, June 14, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 15 researchers as recipients of the 2024 Urology Care Foundation Research Scholar Awards.
  • Research Scholar Awards support future research leaders and ensure they receive the necessary training and guidance for a successful research career.
  • “The Urology Care Foundation is committed to enhancing global urologic health by funding research, offering patient education resources, and endorsing humanitarian efforts,” said Harris M. Nagler, MD, FACS, President of the Urology Care Foundation.
  • I look forward to seeing their progress and results over the next couple of years.”
    To learn more about the Urology Care Foundation Research Scholar Awards visit: https://www.auanet.org/research-and-data/research-awards/aua-funding/res...

Dr. Hari Saini Launches Prestigious Grant to Shape Future Healthcare Leaders: Apply Now for the Dr. Hari Saini Grant for Medical Assistants and Secure Your Path to Excellence

Retrieved on: 
목요일, 6월 13, 2024
Health, Cedars-Sinai Medical Center, Medicine, Cardiology, FACC, Education, Interventional cardiology, Patient, University

The Dr. Hari Saini Grant for Medical Assistants, established in honor of Dr. Hari Saini's dedication to exceptional patient care and medical advancement, seeks to recognize individuals who exemplify Dr. Saini's core values of excellence, compassion, and patient-centered care.

Key Points: 
  • The Dr. Hari Saini Grant for Medical Assistants, established in honor of Dr. Hari Saini's dedication to exceptional patient care and medical advancement, seeks to recognize individuals who exemplify Dr. Saini's core values of excellence, compassion, and patient-centered care.
  • Applicants for the Dr. Hari Saini Grant for Medical Assistants are invited to share their unique perspective on the future of healthcare in 500 words or less.
  • The deadline to apply for the Dr. Hari Saini Grant for Medical Assistants is January 15, 2025.
  • Dr. Hari Saini, MD, FACC, FSCAI, RVPI, is a distinguished interventional cardiologist renowned for his unwavering dedication to patient care and medical excellence.

Clinical Data Published at ASCO Support the Potential of VIVUS’ PANCREAZE® to Stabilize Weight and Improve Gastrointestinal Outputs in Patients with Pancreatic Cancer

Retrieved on: 
목요일, 5월 30, 2024
PERT, MPH, Patient, PDAC, SOC, Anemia, Gastrointestinal tract, Bromelain, Clinical trial, Cachexia, Safety, Serum, Cancer, Argyreia nervosa, Pancreatic cancer, Abstract, Steatorrhea, ASCO, Cedars-Sinai Medical Center, Associate, Exocrine pancreatic insufficiency, Society, Weight loss, Cystic fibrosis, Malnutrition, Quality of life, Standard of care, Annual general meeting, Chronic pancreatitis, Pharmaceutical industry

The data also suggest that PANCREAZE may reduce stool frequency and improve stool consistency.

Key Points: 
  • The data also suggest that PANCREAZE may reduce stool frequency and improve stool consistency.
  • VIVUS provided PANCREAZE and funding to support the clinical trial.
  • PANCREAZE is approved in the United States and Canada for the treatment of EPI due to cystic fibrosis or other conditions.
  • The data was published in an ePoster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024, in Chicago, IL and online.

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
화요일, 5월 21, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SBS, DDW, White, Short bowel syndrome, Diagnosis, Food, NDA, Clinical trial, FDA, FRCS, Medication, Overalls, Safety, Ironwood Pharmaceuticals, Marketing, FACS, CIC, Transplant, STARS, Cedars-Sinai Medical Center, HCP, IBS, MBBS, Principal, PS, Pharmaceutical industry

Apraglutide is the first and only investigational once-weekly GLP-2 analog that has successfully demonstrated positive results in a Phase III placebo-controlled study.

Key Points: 
  • Apraglutide is the first and only investigational once-weekly GLP-2 analog that has successfully demonstrated positive results in a Phase III placebo-controlled study.
  • Treatment effect with relative PS volume reduction was observed from week 8 onward (-8% vs -1.6% placebo, p=0.002).
  • Three additional colon-in-continuity patients achieved enteral autonomy by week 48: 7/56 [12.5%] apraglutide vs 2/27 placebo [7.4%], p=0.387.
  • Apraglutide was well-tolerated, with no new safety signals identified and the safety profile was consistent with previous apraglutide studies.

mBIOTA Labs Announces Results from First Prospective Clinical Trial of Novel, Palatable Elemental Diet in Patients with SIBO and IMO

Retrieved on: 
월요일, 5월 20, 2024
Biotechnology, Fitness & Nutrition, Health, Clinical Trials, Taste, Patient, Clinical trial, Cedars-Sinai Medical Center, Labs, SIBO, Gastroenterology, Diet, Gastrointestinal disease, Multimedia, Pharmaceutical industry

mBIOTA Labs, a medical food company revolutionizing oral nutrition through their proprietary palatable elemental diet, mBIOTA Elemental™, today announced the initial study results of their first prospective clinical trial assessing the efficacy of the mBIOTA Elemental™ diet in patients with small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), or a combination of the two.

Key Points: 
  • mBIOTA Labs, a medical food company revolutionizing oral nutrition through their proprietary palatable elemental diet, mBIOTA Elemental™, today announced the initial study results of their first prospective clinical trial assessing the efficacy of the mBIOTA Elemental™ diet in patients with small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), or a combination of the two.
  • Notably, participants achieved a groundbreaking 100% compliance rate, with all patients successfully completing the two-week course of the mBIOTA Elemental™ diet.
  • “With mBIOTA Elemental™, we are prioritizing the patient experience without sacrificing efficacy and, as indicated in the results of our first clinical trial, creating an incredible opportunity for gastroenterologists to help patients manage GI dysfunction.
  • The introduction of mBIOTA’s truly palatable elemental diet this year now offers patients an approachable and clinically reliable option to manage GI disorders like SIBO and IMO.

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Retrieved on: 
화요일, 5월 7, 2024
CRAC, Poster, DDW, Cedars-Sinai Medical Center

LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation by a collaborator from Cedars-Sinai Medical Center at the upcoming Digestive Disease Week (DDW) 2024 being held May 18-21 in Washington, DC and virtually.

Key Points: 
  • LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation by a collaborator from Cedars-Sinai Medical Center at the upcoming Digestive Disease Week (DDW) 2024 being held May 18-21 in Washington, DC and virtually.
  • Details for the presentation are as follows:

Hoag Family Cancer Institute Welcomes Oncology 'Power Couple'

Retrieved on: 
목요일, 4월 25, 2024
Cloud, Circle, Cancer, University, D.S, Hospital, Drug development, Hematology, Immunotherapy, Oncology, Research, Pathology, University of Texas System, Cedars-Sinai Medical Center, Patient, Medicine, Lung, Breast cancer, Nursing

NEWPORT BEACH, Calif., April 25, 2024 /PRNewswire/ -- Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute.

Key Points: 
  • Husband and wife team Alain Mita, M.D., and Monica Mita, M.D., join Hoag from Cedars-Sinai Medical Center as new program directors
    NEWPORT BEACH, Calif., April 25, 2024 /PRNewswire/ -- Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute.
  • Dr. Monica Mita joins Hoag as co-director of early phase development therapy and co-director of breast medical oncology.
  • These advanced treatments offered at the Hoag Family Cancer Institute are usually only available at large academic cancer centers, which makes Hoag so unique."
  • He also completed an advanced oncology drug development fellowship program at the Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center.

Dr. Farzin Kabaei, Leading Robotic Hip and Knee Replacement Surgeon, Recognized as Top Patient Rated Doctor for 2024

Retrieved on: 
수요일, 4월 10, 2024
UCLA, Knee, Hip, Trauma, Medical Board of California, Cedars-Sinai Medical Center, Orthopedic surgery, Patient, Professional, LOS, Regenerative medicine, Multimedia, Organization, Specialization, Medical device

LOS ANGELES, April 10, 2024 /PRNewswire-PRWeb/ -- Utilizing a multi-disciplinary approach at his state-of-the-art medical center in Los Angeles, California, Dr. Kabaei's dedication to excellence has earned him widespread acclaim from satisfied patients and recognition from esteemed organizations like Find Local Doctors. Known for his surgical skill and professionalism, Dr. Kabaei has garnered numerous five-star ratings and glowing reviews from patients across various online platforms.

Key Points: 
  • Dr. Farzin Kabaei, renowned for his expertise in robotic joint replacements, has been honored as a Top Patient Rated Doctor for 2024.
  • Founder of Robotic Hip and Knee Replacement LA, Dr. Kabaei and his team employ a comprehensive approach to treating knee, hip, and shoulder conditions, striving to enhance mobility and alleviate pain for their patients.
  • With expertise in the Mako™ robotic joint replacement system, Dr. Kabaei provides personalized care, including same-day knee and hip joint replacement surgery.
  • Dr. Farzin Kabaei, Robotic Hip and Knee Replacement LA, 310-792-9300, [email protected] , https://www.robotichipandkneereplacementla.com/
    View original content to download multimedia: https://www.prweb.com/releases/dr-farzin-kabaei-leading-robotic-hip-and-...

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

Retrieved on: 
금요일, 4월 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
금요일, 4월 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.